BUY
They report next week. Not sure how it'll pay out because of the slower uptake of their 4th booster shot, but they have an incredible pipeline.
Pharma & Healthcare

Unlock the latest expert's opinion. Its free

Create a FREE account to see the latest opinions & get alerts about when to buy, sell or hold stocks

Unlock the latest opinion & get signals
premium

It’s a Panic-proof Portfolio opinion which is available only for Premium members

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK
(A Top Pick Jul 07/22, Down 30.4%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with MRNA has triggered its stop at $120. To remain disciplined, we recommend covering the position at this time.
Pharma & Healthcare
COMMENT
It has suffered enough. A well-run company, but shares can fall lower. Enough is enough.
Pharma & Healthcare
premium

It’s a Panic-proof Portfolio opinion which is available only for Premium members

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

TOP PICK
Stockchase Research Editor: Michael O'Reilly Trading at only 5x earnings, this is one of the least expensive stocks in the S&P500. The company is looking to expand its COVID vaccine in Europe and the US for children under 6 years. Recently reported earnings smashed analyst expectations by over 65% and is generating a ROE over 120%. The company has been prudently using a small portion of cash reserves to help aggressively buy back shares and retire debt. We recommend a stop loss at $120, looking to achieve $228 -- upside potential over 42%. Yield 0% (Analysts’ price target is $228.00)
Pharma & Healthcare
BUY
Biotechs have strong balance sheets, better than a few years ago. Likes this as well as Amgen. Better to buy individual biotech stocks over ETFs.
Pharma & Healthcare
BUY
Has lightened his holding (and all his stocks) because of this market, but it remains one of the cheapest stocks out there with a lot of cash in order to buy another company. Their drug pipeline continues to grow. It's the best biotech out there.
Pharma & Healthcare
DON'T BUY
Chart has come full circle. Covid vaccine was a tremendous short-term win for the company and society. Revenues are trailing off for the next 2 years. Avoid the rockets and torpedoes. Look at PFE instead.
Pharma & Healthcare
COMMENT
They report Wednesday. They made a lot of cash during the pandemic, but they need to expand and can't be a one-trick pony. Need to broaden their portfolio.
Pharma & Healthcare
BUY on WEAKNESS
Shares are plunging today. They sold over $18 billion of vaccines for 2022. All vaccine stocks have fallen for the same reason: Covid is ending. He's short calls and long puts for Moderna (has been so for many months). Post-vaccine world, he thinks this will be the most-valuable healthcare company, because they have a platform that's grown from 21 therapeutics and vaccines to over 40 in the span of a year. The future is extremely bright. But biotech stocks are event-driven. So, no events, then shorting happens and sellers get impatient.
Pharma & Healthcare
WATCH
It made a ton of money since Covid, but it hasn't done much with that cash and didn't develop a pill treatment like Pfizer. He wishes they would buy weaker biotechs with that cash to grow. He expects/hope that.
Pharma & Healthcare
DON'T BUY
Fallen a lot recently. If we believe that Covid becomes endemic and we don't all need shots, what's going to happen to MRNA? Crazy cheap at 8-9x next year's earnings, beautiful balance sheet, technology works, but what's the next catalyst? He tends to stay away from biotechs and pharmas, as the science is too hard to understand.
Pharma & Healthcare
COMMENT
Among the 10 top performers on the S&P of 2021 #3, up 143%. He doubts MRNA can repeat this increase unless everybody gets a fourth dose of their vaccine or can diversify into, say, cancer vaccines. He loves management, but the stock isn't pricing in the chance the Omicron will come and go quickly (and result in a bad kind of herd immunity).
Pharma & Healthcare
BUY
Believes Moderna is example of how pharmaceuticals changing (increased vaccine turnaround time). Good buying opportunity at current price. Strong pipeline in many different areas. Opportunity to use Covid-19 education towards other diseases/viruses.
Pharma & Healthcare
premium

It’s a Buzzing Stocks opinion which is available only for Premium members

It's the review of the most popular stocks on social media. It's posted weekly to give you another view on the trending stocks, so you will not waste your precious time on scrolling social media feeds.

TOP PICK
One of the best drug pipeline in the industry and trading under 10x earnings according to Stephen Weiss. Social media mentions are up 1056% over the last 7 days.
Pharma & Healthcare
DON'T BUY
Got hammered today, but they need to prove they can deliver vaccines to market.
Pharma & Healthcare
Showing 1 to 15 of 34 entries

Moderna(MRNA-Q) Rating

Ranking : 4 out of 5

Bullish - Buy Signals / Votes : 6

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 3

Total Signals / Votes : 9

Stockchase rating for Moderna is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Moderna(MRNA-Q) Frequently Asked Questions

What is Moderna stock symbol?

Moderna is a American stock, trading under the symbol MRNA-Q on the NASDAQ (MRNA). It is usually referred to as NASDAQ:MRNA or MRNA-Q

Is Moderna a buy or a sell?

In the last year, 9 stock analysts published opinions about MRNA-Q. 6 analysts recommended to BUY the stock. 3 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Moderna.

Is Moderna a good investment or a top pick?

Moderna was recommended as a Top Pick by on . Read the latest stock experts ratings for Moderna.

Why is Moderna stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Moderna worth watching?

9 stock analysts on Stockchase covered Moderna In the last year. It is a trending stock that is worth watching.

What is Moderna stock price?

On 2022-11-28, Moderna (MRNA-Q) stock closed at a price of $175.38.